CSTL 주식 개요 캐슬 바이오사이언스는 분자 진단 회사로 피부암, 바렛 식도, 포도막 흑색종, 정신 건강 질환의 진단 및 치료를 위한 검사 솔루션을 제공합니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Castle Biosciences, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Castle Biosciences 과거 주가 현재 주가 US$26.66 52주 최고치 US$35.84 52주 최저치 US$16.97 베타 0.89 1개월 변경 -11.96% 3개월 변경 사항 -5.09% 1년 변경 사항 23.54% 3년 변화 -41.57% 5년 변화 -24.96% IPO 이후 변화 24.58%
최근 뉴스 및 업데이트 더 많은 업데이트 보기
Castle Biosciences, Inc. Highlights Progress for Its Pipeline Atopic Dermatitis Gene Expression Profile Test Dec 24
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma Dec 13
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway Dec 12
Castle Biosciences, Inc. Announces the Latest Data from Its Prospective, Multicenter Decide Study Exploring the Impact of Integrating Decisiondx-Melanoma Test Results into SLNB Decision-Making for Patients Recently Diagnosed with Melanoma Nov 07
Castle Biosciences, Inc. Increases Earnings Guidance for the Year 2024 Nov 05
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%? Oct 15
Castle Biosciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 14
Castle Biosciences to Present New Data on Decisiondx-Melanoma and Decisiondx-Um At 21St International Congress of the Society for Melanoma Research Oct 09
Castle Biosciences, Inc.s’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma Sep 30
Castle Biosciences, Inc. Announces the Publication of New Study in Future Oncology Sep 05
Castle Biosciences: Inflection Into Profitability Aug 16
Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts Aug 11
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates Aug 08
Castle Biosciences, Inc. Revises Financial Guidance for the Full Year 2024 Aug 06
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up Aug 04
Castle Biosciences, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 16
Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment? Jul 12
Castle Biosciences, Inc. Announces that AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher Test Jun 24
Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis Jun 01
Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology May 31
Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival (MFS) in Patients Diagnosed with UM May 10
Consensus estimates of losses per share improve by 28% May 10
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 04
Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024 May 03
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark Apr 30
Founder notifies of intention to sell stock Apr 15
Castle Biosciences, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 12
Castle Biosciences, Inc., Annual General Meeting, May 23, 2024 Apr 11
Independent Chairman of the Board notifies of intention to sell stock Apr 07
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress Apr 05
Castle Biosciences, Inc. Announces Board Changes Mar 28
Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test Mar 08
Founder notifies of intention to sell stock Mar 08
Consensus estimates of losses per share improve by 26% Mar 06
New minor risk - Shareholder dilution Mar 01
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 01
Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024 Feb 29
Castle Biosciences, Inc. to Report Second Half, 2023 Results on Feb 28, 2024 Feb 08
Independent Chairman of the Board notifies of intention to sell stock Feb 08
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects Jan 27
Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii Jan 14
Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Jan 08
Forecast to breakeven in 2026 Dec 31
Founder exercised options and sold US$362k worth of stock Dec 13
Independent Chairman of the Board notifies of intention to sell stock Dec 06
Founder notifies of intention to sell stock Nov 24
Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder Nov 10
Consensus estimates of losses per share improve by 21% Nov 09 Castle Biosciences, Inc. Announces New Data Showing the Ability of Its Pipeline Test in Development to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis
New minor risk - Shareholder dilution Nov 04
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 03
Castle Biosciences, Inc. Raises Earnings Guidance for the Full Year 2023 Nov 03
Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans Oct 31
Castle Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Castle Biosciences, Inc. Announces New Study Demonstrating DecisionDx-Melanoma Outperforms a Nomogram Developed at the Memorial Sloan Kettering Cancer Center Oct 06
Castle Biosciences, Inc. Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus Oct 05
Castle Biosciences, Inc. Announces TissueCypher Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus Sep 15
Castle Biosciences, Inc. Announces Data from a Study Showing the Addition of Drug-Drug Interactions and Lifestyle Factors to Drug-Gene Interactions Sep 12
Consensus estimates of losses per share improve by 12% Aug 09
Founder notifies of intention to sell stock Aug 06
Castle Biosciences, Inc. Raises Revenue Guidance for the Full Year 2023 Aug 05
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 03
Independent Chairman of the Board notifies of intention to sell stock Jul 10
Castle Biosciences to Present New DecisionDx®-Melanoma Data at the American Head & Neck Society's 11th International Conference on Head and Neck Cancer Jul 08
Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive Jun 13
Castle Biosciences, Inc. Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging Jun 13
Independent Director recently bought US$69k worth of stock Jun 11
Price target decreased by 11% to US$39.75 Jun 06
Castle Biosciences, Inc. to Share New Data on DecisionDx-Melanoma and DecisionDx-UM at the 2023 ASCO Annual Meeting Jun 04
Consensus EPS estimates fall by 16%, revenue upgraded May 10
Founder notifies of intention to sell stock May 08
Castle Biosciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023 May 05
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 05
Consensus EPS estimates fall by 11%, revenue upgraded Mar 07
Full year 2022 earnings: EPS exceeds analyst expectations Mar 01
Castle Biosciences, Inc. Publishes Data from Prospective, Multicenter Study, Called DECIDE Feb 10
Castle Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 08
Founder notifies of intention to sell stock Feb 05
Castle Biosciences, Inc. Revises Revenue Guidance for the for Full-Year 2022 Jan 09
Founder exercised options and sold US$141k worth of stock Dec 14
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors Nov 16
Founder notifies of intention to sell stock Nov 16
Founder notifies of intention to sell stock Nov 11
Independent Chairman of the Board notifies of intention to sell stock Nov 05
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 03
Castle Biosciences, Inc. Revises Revenue Guidance for the Full Year 2022 Nov 03
Castle Biosciences, Inc. Presents New Data from Collaboration with the National Cancer Institute's (NCI) Surveillance, Epidemiology and End Results (SEER) Program Oct 28
Castle Biosciences, Inc. Announces New Data Showing That the Use of Tissuecypher® Barrett’S Esophagus Test Results Can Significantly Improve Management Decisions for Barrett’S Esophagus (Be) Patients with Low-Grade Dysplasia (Lgd)To Improve Health Outcomes Oct 26 Castle Biosciences, Inc. Announces New Data from Prospective, Multicenter DECIDE1 Study Oct 21
Castle Biosciences, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 20
Castle Biosciences, Inc. Announces Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management Oct 14
Castle Biosciences, Inc. to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting Oct 11
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx(R)-Melanoma and Clinicopathologic Factors Provides Optimized, Survival Prognoses for Patients with Cutaneous Melanoma Sep 24
Castle Biosciences, Inc. Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests At Maui Derm Np+Pa Fall 2022 Conference Sep 22
Consensus revenue estimates increase by 10% Aug 15
Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL) Aug 14
Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year 2022 Aug 09 주주 수익률 CSTL US Healthcare US 마켓 7D -3.0% -0.4% -1.1% 1Y 23.5% -10.3% 22.4%
전체 주주 수익률 보기
수익률 대 산업: CSTL 지난 1년 동안 -10.3 %를 반환한 US Healthcare 산업을 초과했습니다.
수익률 대 시장: CSTL 지난 1년 동안 22.4 %를 반환한 US 시장과 일치했습니다.
가격 변동성 Is CSTL's price volatile compared to industry and market? CSTL volatility CSTL Average Weekly Movement 7.3% Healthcare Industry Average Movement 7.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.6% 10% least volatile stocks in US Market 3.1%
안정적인 주가: CSTL 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: CSTL 의 주간 변동성 ( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 캐슬 바이오사이언스는 피부암, 바렛 식도, 포도막 흑색종, 정신 건강 질환의 진단 및 치료를 위한 검사 솔루션을 제공하는 분자 진단 회사입니다. 침습성 피부 흑색종 진단을 받은 환자의 전이 위험을 파악하는 위험 계층화 유전자 발현 프로파일(GEP) 테스트인 DecisionDx-Melanoma와 피부 편평세포암 환자를 위한 독자적인 위험 계층화 GEP 테스트인 DecisionDx-SCC를 제공합니다; 진단하기 어려운 멜라닌 세포 병변을 가진 환자를 위한 검사, 마이패스 멜라노마(MyPath Melanoma), 비이형성, 무기형성 또는 저등급 이형성 바렛식도 환자에서 향후 고등급 이형성증 및 식도암 발생을 예측하는 공간 오믹스 검사, 티슈사이퍼(TissueCypher) 등이 있습니다. 또한, 포도막 흑색종 환자의 전이 위험을 예측하는 독자적인 위험도 계층화 GEP 검사인 '디시전디엑스-UM 검사'와 주요 우울장애, 조현병, 조울증, 불안 장애, 사회 공포증, 강박성 성격 장애, 외상 후 스트레스 장애, 주의력 결핍 과잉 행동 장애의 약물 치료를 안내하는 약물 유전체 검사 '아이디제네틱스'를 제공하고 있습니다.
자세히 보기 Castle Biosciences, Inc. 기본 사항 요약 Castle Biosciences 의 수익과 매출은 시가총액과 어떻게 비교하나요? CSTL 기본 통계 시가총액 US$751.44m 수익(TTM ) US$6.08m 수익(TTM ) US$311.88m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) CSTL 손익 계산서(TTM ) 수익 US$311.88m 수익 비용 US$56.45m 총 이익 US$255.43m 기타 비용 US$249.36m 수익 US$6.08m
주당 순이익(EPS) 0.22 총 마진 81.90% 순이익 마진 1.95% 부채/자본 비율 2.3%
CSTL 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/30 09:58 장 마감 주가 2024/12/30 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Castle Biosciences, Inc. 9 애널리스트 중 9 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Catherine Ramsey Schulte Baird Mark Massaro BTIG Kyle Mikson Canaccord Genuity
6 더 많은 분석가 보기 
